Across 30 BRAFV600E mutant melanoma cell lines that were screened against BRAF and MEK inhibitors within the Cancer Cell Line Encyclopedia (CCLE) project [29], the YAP1/TAZ 22 target gene score correlated significantly with resistance to MAPK inhibitors, the MITFlow/AXLhigh phenotype, and the expression of known resistance marker genes (Fig. 2b) [24]. The gene discussed is MAP2K7; the disease is cancer.